

ASX / Media Release

AdAlta major shareholder, Yuuwa Capital, fund expiry extended to 2022

MELBOURNE Australia, 12 March, 2019: AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate toward clinical development is pleased to announce that its major shareholder, Yuuwa Capital, has confirmed extension of its fund for an additional three years.

Yuuwa Capital is a Perth-based venture capital firm and is AdAlta's largest shareholder with a holding of 45.97%. Yuuwa's fund was established in 2009 with investment from the Australian Federal Government's Innovation Investment Fund (IIF) program and private investors. The original end date for Yuuwa's fund was in late 2019. Under the fund extension approved by its Limited Partners, the life of the Yuuwa Capital fund has been extended until late 2022.

Yuuwa Capital General Partner and AdAlta Non-Executive Director, Dr James Williams commented: "Yuuwa is delighted to confirm its ongoing support of AdAlta. We intend to continue to hold our significant equity interest in AdAlta through key upcoming value inflection points including completion of GMP manufacture, formal pre-clinical toxicology studies and first in human clinical studies for AD-214. Yuuwa's significant investment into AdAlta reflects our confidence in the technology and in the AdAlta team as they progress into human clinical trials during the next 12 months."

AdAlta CEO, Sam Cobb commented: "Yuuwa has been a substantial and supportive shareholder in AdAlta for almost 8 years. This extension reflects Yuuwa's longstanding conviction in the considerable value yet to be realised in our Company."

-ENDS-

Notes to Editors

About AdAlta Limited

AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.

We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, which was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is developing its lead i-body candidate, AD-214, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.

The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.

Further information can be found at: www.adalta.com.au.

For more information, please contact:

AdAlta Limited

Sam Cobb, CEO

Tel: +61 (0)3 9479 5159

E: s.cobb@adalta.com.au